Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).

Trial Profile

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2018

At a glance

  • Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Abacavir; Lamivudine; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms Advanz-4
  • Most Recent Events

    • 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 12 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top